Utility of boron in dermatology

References

• Pizzorno L. Nothing Boring About Boron. Integr Med (Encinitas). 2015;14:35–48.
   PubMedGoogle Scholar
• Hunter P. Not boring at all. Boron is the new carbon in the quest for novel drug candidates. EMBO Rep. 2009;10:125–128.
   PubMed Web of Science ®Google Scholar
• Baker SJ, Tomsho JW, Benkovic SJ. Boron-containing inhibitors of synthetases. Chem Soc Rev. 2011;40:4279.
   PubMed Web of Science ®Google Scholar
• Yang W, Gao X, Wang B. Boronic acid compounds as potential pharmaceutical agents. Med Res Rev. 2003;23:346–368.
   PubMed Web of Science ®Google Scholar
• Baker SJ, Ding CZ, Akama T, et al. Therapeutic potential of boron-containing compounds. Future Med Chem. 2009;1:1275–1288.
   PubMed Web of Science ®Google Scholar
• Jeong JC, Jambaldorj E, Kwon HY, et al. Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation. Medicine (Baltimore). 2016;95:e2635.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–1634.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Hungria VTM, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127:713–721.
   PubMed Web of Science ®Google Scholar
• Wada Y, Iyoda M, Saito T, et al. Light-chain deposition disease successfully treated with bortezomib in an elderly patient: a case report and review of the literature. Intern Med. 2015;54:2893–2898.
   PubMed Web of Science ®Google Scholar
• Shah N, Meouchy J, Qazi Y. Bortezomib in kidney transplantation. Curr Opin Organ Transplant. 2015;20:652–656.
   PubMed Web of Science ®Google Scholar
• Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20(5):22608.
   Google Scholar
• Del Rosso JQ, Plattner JJ. From the test tube to the treatment room: fundamentals of boron-containing compounds and their relevance to dermatology. J Clin Aesthet Dermatol. 2014;7:13–21.
   PubMedGoogle Scholar
• Wigger-Alberti WZ. Dermal tolerability and preliminary efficacy of AN2728 and A2898, novel boron-based small molecules, in the treatment of psoriasis. Poster presented at: Annual Meeting of the European Society for Dermatologic Research; 2011 Sep 7–10; Barcelona, Spain.
   Google Scholar
• Akama T, Baker SJ, Zhang YK, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett. 2009;19(8):2129–2132.
   Google Scholar
• Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs. 2007;8:364–372.
   PubMed Web of Science ®Google Scholar
• Jarnagin K, Chanda S, Coronado BD, et al. Crisaborole topical ointment, 2% : a nonsteroidal, topical, anti - inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol. 2016;15:390–396.
   PubMed Web of Science ®Google Scholar
• Freund YR, Akama T, Alley MRK, et al. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett. 2012;586:3410–3414.
   PubMed Web of Science ®Google Scholar
• SJ, Baker *, Y-K, Zhang, T, Akama, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem. 2006;49(15):4447–4450.
   Google Scholar
• Jinna S, Finch J. Spotlight on tavaborole for the treatment of onychomycosis. Drug Des Devel Ther. 2015;9:6185–6190.
   PubMed Web of Science ®Google Scholar
• Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007;316:1759–1761.
   PubMed Web of Science ®Google Scholar
• Zane LT, Kircik L, Call R, et al. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure study. Pediatr Dermatol. 2016;33:380–387.
   PubMed Web of Science ®Google Scholar
• Zane LT, Hughes MH, Shakib S. Tolerability of crisaborole ointment for application on sensitive skin areas: a randomized, double-blind, vehicle-controlled study in healthy volunteers. Am J Clin Dermatol. 2016;17(5):519–526.
   PubMed Web of Science ®Google Scholar
• Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75:494–503e4.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Gebauer K, Spelman L, et al. Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study. J Drugs Dermatol. 2015;14:1108–1112.
   PubMed Web of Science ®Google Scholar
• Stein Gold LF, Spelman L, Spellman MC, et al. A Phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol. 2015;14:1394–1399.
   PubMed Web of Science ®Google Scholar
• Beutner KR, Sanders VH. An open-label, multi-dose study of the absorption and systemic pharmacokinetics of AN2690 applied as a 7.5% solution to all toenails of adult patients with moderate to severe onychomycosis. 2007.
   Google Scholar
• Hui X, Baker SJ, Wester RC, et al. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci. 2007;96:2622–2631.
   PubMed Web of Science ®Google Scholar
• Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, et al. The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. J Drugs Dermatol. 2014;13:1124–1132.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62–69.
   PubMed Web of Science ®Google Scholar
• Evans JM, Wang AL, Elewski BE. Successful treatment of paecilomyces lilacinus onychomycosis with efinaconazole and tavaborole. Skin Appendage Disord. 2015;1:169–171.
   Web of Science ®Google Scholar
• Vlahovic T, Coronado D, Chanda S, et al. Evaluation of the appearance of nail polish following daily treatment of ex vivo human fingernails with topical solutions of tavaborole or efinaconazole. J Drugs Dermatol. 2016;15:89–94.
   PubMed Web of Science ®Google Scholar
• Baker SJ, Zhang Y-K, Akama T, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem. 2006;49:4447–4450.
   PubMed Web of Science ®Google Scholar
• Ciaravino V, Plattner J, Chanda S. An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013;54:338–346.
   PubMed Web of Science ®Google Scholar
• Zhao H, Palencia A, Seiradake E, et al. Analysis of the resistance mechanism of a benzoxaborole inhibitor reveals insight into the leucyl-tRNA synthetase editing mechanism. ACS Chem Biol. 2015;10:2277–2285.
   PubMed Web of Science ®Google Scholar
• Ciaravino V, Coronado D, Lanphear C, et al. Tavaborole, a novel boron-containing small molecule for the topical treatment of onychomycosis, is noncarcinogenic in 2-year carcinogenicity studies. Int J Toxicol. 2014;33:419–427.
   PubMed Web of Science ®Google Scholar
• Dong C, Virtucio C, Zemska O, et al. Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes. J Pharmacol Exp Ther. 2016;358:413–422.
   PubMed Web of Science ®Google Scholar
• Ban HS, Nakamura H. Boron-based drug design. Chem Rec. 2015;15:616–635.
   PubMed Web of Science ®Google Scholar
• Abeck D, Strom K. Optimal management of atopic dermatitis. Am J Clin Dermatol. 2000;1:41–46.
   PubMedGoogle Scholar
• Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931–936.
   PubMed Web of Science ®Google Scholar
• Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4:1–191.
   PubMedGoogle Scholar
• Yan J, Wang X, Chen S. Systematic review of severe acute liver injury caused by terbinafine. Int J Clin Pharm. 2014;36:679–683.
   PubMed Web of Science ®Google Scholar
• Madani S, Barilla D, Cramer J, et al. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol. 2002;42:1211–1218.
   PubMed Web of Science ®Google Scholar
• Vickers AE, Sinclair JR, Zollinger M, et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999;27:1029–1038.
   PubMed Web of Science ®Google Scholar